Main Article Content
The present study was mainly based upon the “Process Optimization of Venlafaxine Hydrochloride tablets prepared” by wet granulation technique using different concentration of superdisintegrants. Venlafaxine, hydrochloride is a structurally novel phenethyl bicyclic antidepressant, and is usually categorized as a serotonin–norepinephrine reuptake inhibitor (SNRI) but it has been referred to as a serotonin–norepinephrine– dopamine reuptake inhibitor. The objective of the present study is to develop a pharmaceut ically stable, cost effective and quality improved venlafaxine hydrochloride tablets. In the present study the main objective is directed towards development and evaluation of venlafaxine hydrochloride tablets to achieve faster dissolution to match the innovator product. It involves preformulation studies specifically compatibility studies for possible drug-excipient interactions using Fourier Transform Infrared Spectrophotometer. Evaluation of pre compression parameters. Design and development of various formulations. Evaluation of post compression parameters of the formulated tablets. To carry out in vitro drug release studies. To carryout accelerated stability studies as per ICH guidelines.